Alan Barge
Chief Executive Officer 4C Biomed
Seminars
Thursday 3rd December 2026
Panel Discussion: What Evidence Gives Us Confidence That a Model Will Translate?
1:50 pm
- How can clinical observations and reverse translational insights be used to improve future model development and regulatory confidence?
- What role should patient-derived and human-relevant tumour models play in identifying novel targets and improving candidate selection?
- Which biological, translational, or clinical endpoints provide the strongest evidence that a programme is ready for progression?
- Audience Q&As
Thursday 3rd December 2026
Identifying Novel Immunotherapy Targets Using Human-Relevant Tumour Models
1:30 pm
- Leveraging patient-derived tumour systems to identify and validate novel targets across both tumour and immune cell populations
- Understanding how human-relevant screening approaches can uncover therapeutic opportunities missed by conventional preclinical models
- Evaluating the translational relevance of novel immunotherapy targets and therapeutic strategies in tumours resistant to first-generation checkpoint inhibitors
